Carney Adam C
J Psychosoc Nurs Ment Health Serv. 2013 Aug;51(8):11-8. doi: 10.3928/02793695-20130709-01. Epub 2013 Jul 18.
Quetiapine (Seroquel(®)) is a potent U.S. Food and Drug Administration (FDA)-approved antipsychotic agent that has been used extensively for off-label indications. The current study was performed to ascertain the efficacy of some of the most prevalent off-label uses of this agent. An extensive search of electronic databases was completed using the search terms quetiapine or Seroquel, off-label and anxiety, substance abuse, dementia, delirium, personality disorder, insomnia, and sleep. Data were predictably mixed according to the indication being examined. The strongest evidence exists for anxiety and delirium. Moderate evidence exists for quetiapine as a pharmacological intervention for insomnia, dementia, and specific personality disorders. Evidence for quetiapine as a treatment for substance abuse is limited. More data are needed to establish specific dosing regimens for off-label uses and to examine the dose relationship to metabolic side effects and extrapyramidal side effects to determine whether various off-label uses justify the risk incurred with using this powerful drug.
喹硫平（思瑞康（®））是一种经美国食品药品监督管理局（FDA）批准的强效抗精神病药物，已被广泛用于治疗未获批准的适应症。本研究旨在确定该药物一些最常见的未获批准用途的疗效。使用搜索词“喹硫平”或“思瑞康”、“未获批准”以及“焦虑症”“药物滥用”“痴呆症”“谵妄”“人格障碍”“失眠”和“睡眠”对电子数据库进行了全面检索。根据所研究的适应症，数据呈现出不同情况。焦虑症和谵妄方面的证据最为充分。有中等证据表明喹硫平可作为治疗失眠、痴呆症和特定人格障碍的药物干预手段。关于喹硫平治疗药物滥用的证据有限。需要更多数据来确定未获批准用途的具体给药方案，并研究剂量与代谢副作用及锥体外系副作用之间的关系，以确定各种未获批准用途是否值得承担使用这种强效药物所带来的风险。
